EA201791732A1 - Безопасное введение десмопрессина - Google Patents
Безопасное введение десмопрессинаInfo
- Publication number
- EA201791732A1 EA201791732A1 EA201791732A EA201791732A EA201791732A1 EA 201791732 A1 EA201791732 A1 EA 201791732A1 EA 201791732 A EA201791732 A EA 201791732A EA 201791732 A EA201791732 A EA 201791732A EA 201791732 A1 EA201791732 A1 EA 201791732A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- desmopressin
- treatment
- desmopressina
- safe
- diuresis
- Prior art date
Links
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 abstract 2
- 208000004880 Polyuria Diseases 0.000 abstract 2
- 230000009286 beneficial effect Effects 0.000 abstract 2
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 abstract 2
- 229960004281 desmopressin Drugs 0.000 abstract 2
- 230000035619 diuresis Effects 0.000 abstract 2
- 230000027939 micturition Effects 0.000 abstract 2
- 206010021639 Incontinence Diseases 0.000 abstract 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 abstract 1
- 201000010064 diabetes insipidus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 206010029446 nocturia Diseases 0.000 abstract 1
- 230000000422 nocturnal effect Effects 0.000 abstract 1
- 239000007921 spray Substances 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
- A61M15/085—Fixing means therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/27—General characteristics of the apparatus preventing use
- A61M2205/276—General characteristics of the apparatus preventing use preventing unwanted use
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13987108P | 2008-12-22 | 2008-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201791732A1 true EA201791732A1 (ru) | 2018-03-30 |
Family
ID=42168193
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201791732A EA201791732A1 (ru) | 2008-12-22 | 2009-12-21 | Безопасное введение десмопрессина |
| EA201170873A EA028531B1 (ru) | 2008-12-22 | 2009-12-21 | Безопасный способ введения десмопрессина |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201170873A EA028531B1 (ru) | 2008-12-22 | 2009-12-21 | Безопасный способ введения десмопрессина |
Country Status (19)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009021007A1 (en) | 2007-08-06 | 2009-02-12 | Serenity Pharmaceuticals Corporation | Methods and devices for desmopressin drug delivery |
| SG10201509152VA (en) * | 2008-12-22 | 2015-12-30 | Allergan Inc | Intranasal desmopressin administration |
| CA2765221C (en) * | 2009-06-18 | 2017-10-03 | Allergan, Inc. | Safe desmopressin administration |
| EP3024473A1 (en) | 2013-07-23 | 2016-06-01 | Allergan, Inc. | Methods and compositions comprising desmopressin in combination with a 5-alpha reductase inhibitor |
| CN105579057A (zh) * | 2013-07-23 | 2016-05-11 | 阿勒根公司 | 包含与β-3-肾上腺素能受体激动剂组合的去氨加压素的方法和组合物 |
| CA2967390A1 (en) | 2014-11-20 | 2016-05-26 | Allergan, Inc. | Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CS171787B1 (cg-RX-API-DMAC7.html) | 1973-11-09 | 1976-11-29 | ||
| US4148787A (en) | 1976-05-24 | 1979-04-10 | Ferring Ab | Antidiuretically effective polypeptide and a process for preparing the same |
| US4771769A (en) | 1982-12-20 | 1988-09-20 | Schering Corporation | Hand held metered spray dispenser |
| US4548922A (en) | 1983-06-06 | 1985-10-22 | Beth Israel Hospital | Drug administration |
| US4746508A (en) | 1983-06-06 | 1988-05-24 | Beth Israel Hospital Assn. | Drug administration |
| US5731303A (en) | 1985-12-04 | 1998-03-24 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery compositions |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5112804A (en) | 1987-04-01 | 1992-05-12 | Temple University Of The Commonwealth System Of Higher Education | Pharmaceutical composition and method of intranasal administration |
| US4944429A (en) | 1987-08-28 | 1990-07-31 | Schering Corporation | Manually-operable spray dispenser with locking mechanism |
| US5154122A (en) | 1989-10-20 | 1992-10-13 | Sol Goldschmidt | Shipping device for suspended piece goods |
| CN1060980A (zh) * | 1990-10-26 | 1992-05-13 | 蔡东林 | 多用电控自控微型喷雾器 |
| US5314694A (en) | 1990-10-29 | 1994-05-24 | Alza Corporation | Transdermal formulations, methods and devices |
| US5122383A (en) | 1991-05-17 | 1992-06-16 | Theratech, Inc. | Sorbitan esters as skin permeation enhancers |
| US5227169A (en) | 1991-05-17 | 1993-07-13 | Theratech, Inc. | Sorbitan esters as skin permeation enhancers |
| US5212199A (en) | 1991-05-17 | 1993-05-18 | Theratech, Inc. | Sorbitan esters as skin permeation enhancers |
| IT1255895B (it) | 1992-10-20 | 1995-11-17 | Laura Chiodini | Composizioni farmaceutiche contenenti una calcitonina |
| DK0708657T3 (da) * | 1993-06-29 | 2001-10-15 | Ferring Bv | Sammensætninger til nasal administration af desmopression |
| WO1996040332A1 (en) * | 1995-06-07 | 1996-12-19 | O'neil, Christine | Patient controlled drug delivery device |
| US5763398A (en) * | 1996-06-20 | 1998-06-09 | Ferring B.V. | Nasal administration of desmopressin |
| DE19723133A1 (de) | 1997-06-03 | 1998-12-10 | Caideil M P Teoranta Tourmakea | Austragvorrichtung für Medien |
| US7335186B2 (en) | 1998-03-13 | 2008-02-26 | Alexander George Brian O'Neil | Patient controlled drug delivery device |
| AU3421600A (en) | 1999-02-14 | 2000-08-29 | Ing. Erich Pfeiffer Gmbh | Dispenser for flowable media |
| DE19938798A1 (de) | 1999-08-16 | 2001-03-01 | Pfeiffer Erich Gmbh & Co Kg | Spender für Flüssigkeiten oder für zähflüssige oder versprühbare Produkte |
| DE19940236A1 (de) | 1999-08-25 | 2001-03-08 | Pfeiffer Erich Gmbh & Co Kg | Spender mit manuell betätigbarer Ausbringeinrichtung |
| DE10110742A1 (de) | 2001-02-28 | 2002-09-05 | Pfeiffer Erich Gmbh & Co Kg | Spender für Medien |
| US7244703B2 (en) | 2001-06-22 | 2007-07-17 | Bentley Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for peptide treatment |
| PL200833B1 (pl) | 2001-09-21 | 2009-02-27 | Pfeiffer Erich Gmbh & Co Kg | Dozownik z pojemnikiem aplikowanego środka oraz pompka do dozownika |
| US20030232078A1 (en) | 2001-12-19 | 2003-12-18 | Dong Liang C. | Formulation & dosage form for the controlled delivery of therapeutic agents |
| GB0210397D0 (en) * | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
| ITMI20021684A1 (it) * | 2002-07-29 | 2004-01-29 | Therapicon Srl | Composizione farmaceutica di peptide nasale |
| US7186692B2 (en) * | 2002-12-17 | 2007-03-06 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity |
| WO2005046707A1 (en) * | 2003-11-10 | 2005-05-26 | Fein Seymour H | Pharmaceutical compositions including low dosages of desmopressin |
| JP2007513199A (ja) * | 2003-12-08 | 2007-05-24 | ベントレー ファーマスーティカルス,インコーポレイテッド | インスリン治療のための薬学的組成物及び方法 |
| WO2007022345A2 (en) * | 2005-08-17 | 2007-02-22 | Fleming And Company, Pharmaceuticals | Vitamin b12 nasal spray and method of use |
| CN1785448A (zh) * | 2005-11-11 | 2006-06-14 | 广东工业大学 | 医用防染式药雾吸入喷嘴 |
| EP2035031A4 (en) * | 2006-06-08 | 2010-02-24 | Cpex Pharmaceuticals Inc | INSULIN COMPOSITION |
| SG10201509152VA (en) * | 2008-12-22 | 2015-12-30 | Allergan Inc | Intranasal desmopressin administration |
| CA2765221C (en) | 2009-06-18 | 2017-10-03 | Allergan, Inc. | Safe desmopressin administration |
-
2009
- 2009-12-21 SG SG10201509152VA patent/SG10201509152VA/en unknown
- 2009-12-21 EA EA201791732A patent/EA201791732A1/ru unknown
- 2009-12-21 PT PT09796558T patent/PT2381923T/pt unknown
- 2009-12-21 BR BRPI0923557A patent/BRPI0923557A2/pt not_active Application Discontinuation
- 2009-12-21 KR KR1020177017968A patent/KR20170081711A/ko not_active Ceased
- 2009-12-21 CA CA2747998A patent/CA2747998C/en active Active
- 2009-12-21 US US13/141,590 patent/US20120015880A1/en not_active Abandoned
- 2009-12-21 NZ NZ593613A patent/NZ593613A/xx unknown
- 2009-12-21 JP JP2011542539A patent/JP5731396B2/ja active Active
- 2009-12-21 WO PCT/US2009/068962 patent/WO2010075266A2/en not_active Ceased
- 2009-12-21 PL PL09796558.6T patent/PL2381923T5/pl unknown
- 2009-12-21 EA EA201170873A patent/EA028531B1/ru not_active IP Right Cessation
- 2009-12-21 CN CN201610282630.1A patent/CN105963834A/zh active Pending
- 2009-12-21 EP EP09796558.6A patent/EP2381923B2/en active Active
- 2009-12-21 SG SG2011046117A patent/SG172344A1/en unknown
- 2009-12-21 CN CN2009801560968A patent/CN102355888A/zh active Pending
- 2009-12-21 AU AU2009330203A patent/AU2009330203B2/en not_active Ceased
- 2009-12-21 ES ES09796558T patent/ES2692345T5/es active Active
- 2009-12-21 MX MX2011006765A patent/MX2011006765A/es active IP Right Grant
- 2009-12-21 EP EP18174439.2A patent/EP3437633A1/en active Pending
- 2009-12-21 KR KR1020117017070A patent/KR101755042B1/ko active Active
- 2009-12-21 DK DK09796558.6T patent/DK2381923T4/da active
-
2011
- 2011-06-21 IL IL213699A patent/IL213699A/en active IP Right Grant
- 2011-07-22 ZA ZA2011/05420A patent/ZA201105420B/en unknown
-
2015
- 2015-04-09 JP JP2015080138A patent/JP5959076B2/ja active Active
-
2016
- 2016-06-17 JP JP2016120760A patent/JP6389209B2/ja active Active
-
2018
- 2018-06-14 JP JP2018113951A patent/JP2018184407A/ja active Pending
-
2019
- 2019-06-11 US US16/438,040 patent/US20200078542A1/en not_active Abandoned
-
2021
- 2021-05-26 US US17/330,798 patent/US20220126039A1/en not_active Abandoned
-
2023
- 2023-11-10 US US18/506,719 patent/US20240342407A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012000066A (es) | Administracion segura de desmopresina. | |
| EA201170873A1 (ru) | Безопасное введение десмопрессина | |
| NZ599928A (en) | Use of pentosan polysulfate for treatment or prophylaxis of asthma | |
| NZ701038A (en) | Treating acute decompensated heart failure with relaxin | |
| ZA201201060B (en) | Combination of an oxidant,a photosensitizer and a wound healing agent for oral disinfection and treatment or oral disease | |
| NZ593653A (en) | Treatment of inflammatory bowel diseases with mammal beta defensins | |
| NZ594056A (en) | New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein | |
| BR112013015855A2 (pt) | composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica. | |
| BR112012027759A2 (pt) | Conjugados de peptídeos de agonistas de receptores glp-1 e gastrina e seu uso | |
| PL385586A1 (pl) | Nowe analogi insuliny o przedłużonym działaniu | |
| TN2011000217A1 (en) | Pirfenidone treatment for patients with atypical liver fuction | |
| MX2010009447A (es) | Uso de antagonistas de lhrh a dosis no castrantes. | |
| WO2010151755A3 (en) | TREATMENT OF INFLAMMATORY DISEASES USING miR-124 | |
| MX2011007589A (es) | Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20. | |
| MX2013005725A (es) | Composicion para el uso en la prevencion y/o tratamiento de condiciones de la piel y enfermedades de la piel. | |
| EP2216024A3 (en) | Use of Ranolazine for the treatment of cardiovascular diseases | |
| MX2011013296A (es) | Metodos de tratamiento o prevención de enfermedad asociada a influenza con soluciones acuosas con potencial de oxidación-reduccion. | |
| UA102432C2 (ru) | Цитотоксичные конъюгаты с соединением, которое связывает рецептор нейропептиду y | |
| PH12014501629A1 (en) | Treatment of cognitive disorders with (r)-7- chloro -n- (quinuclidin -3-yl) benzo[b] thiophene -2- carboxamide and pharmaceutically acceptable salts thereof | |
| NZ612717A (en) | Treatment of pain associated with dislocation of basal endometrium | |
| UA105191C2 (ru) | Лечение пирфенидоном пациентов с атипической функцией печени | |
| MX2009007247A (es) | Metodo para el tratamiento de afecciones asociadas con actividad aumentada de 5-lipoxigenasa y/o leucotrienos. | |
| BR112013015877A2 (pt) | composto, uso de um composto, métodos de prevenção. tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica. | |
| MX355015B (es) | Uso de hidroxamatos de indolilo e indolinilo para tratar insuficiencia cardiaca o lesión neuronal. | |
| NZ596218A (en) | Bssl antagonists for treatment of inflammatory diseases |